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Introduction
EGF receptor (EGFR) is a type I receptor tyrosine kinase, which 
can be bound at its extracellular domain by growth factors such 
as the EGF. EGF binding triggers dimerization and auto-phos-
phorylation of the receptor, driving the recruitment of effec-
tor proteins and the activation of multiple signaling cascades 
important for cell proliferation, differentiation, migration, and 
survival (Schlessinger, 2000; Lemmon and Schlessinger, 2010). 
EGF binding also causes EGFR internalization into endosomes, 
from where the receptor is either recycled back to the cell sur-
face or degraded by the endo-lysosomal pathway. Degradation 
diminishes EGFR signaling until the amount of receptor at the 
cell surface has been restored by signaling-induced synthesis 
and subsequent transport (Earp et al., 1986; Roepstorff et al., 
2009). Accordingly, EGFR signaling and subsequent cellular 
responses depend on the amount of EGFR at the cell surface, 
which is controlled by the rates of EGFR internalization, re-
cycling, degradation, new synthesis, and transport to the cell 
surface. Deregulations of these control pathways have been 
implicated in a variety of human carcinomas (Yarden and Sli-
wkowski, 2001). The mechanism underlying the transport of 
newly synthesized EGFR to the cell surface after degradation 
has not yet been determined. In eukaryotic cells, receptor pro-
teins are transported from their site of synthesis in the ER to 
their site of action by passing multiple steps within the secre-
tory pathway. Receptor recruitment and sorting decisions are 
already made at discrete ER subdomains called ER exit sites, 
where the protein complex SEC23/24 of the inner coat protein 
complex II (COP II) recognizes sorting signals in receptor cy-
toplasmic domains (Aridor et al., 1998; Kuehn et al., 1998). 
The proteins of the inner COP II coexist in mammalian cells as 
multiple paralogues with potentially divergent functions (Jen-
sen and Schekman, 2011; Zanetti et al., 2011). SEC23 has two 
different paralogues, termed SEC23A and SEC23B, whereas 
SEC24 has four different paralogues, termed SEC24A–D. Al-
though their precise function is largely unknown, paralogues 
of SEC24 have been implicated in the selective recruitment of 
transmembrane proteins into COP II transport vesicles through 
their interaction with the ER export motifs of different proteins 
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(Farhan et al., 2007; Wendeler et al., 2007; Merte et al., 2010; 
Sucic et al., 2011). We and others have previously shown a link 
between EGF ligand stimulation and an adaptation of COP II 
transport vesicle organization and protein transport through the 
secretory pathway (Farhan et al., 2010; Simpson et al., 2012; 
Tillmann et al., 2015). These findings raise the intriguing ques-
tion of whether EGF ligand stimulation induces the transport of 
newly synthesized EGFR to the cell surface through changes in 
the secretory pathway components. Here, we demonstrate that 
EGF stimulation leads to an up-regulation of the inner COP II 
paralogues SEC23B, SEC24B, and SEC24D and that this up- 
regulation requires the transcriptional regulator (TR) RNF11. 
We further show that these SEC23/SEC24 paralogues are nec-
essary for the specific transport of newly synthesized EGFR 
from the ER to the cell surface. We propose that this regula-
tory mechanism is critical for the maintenance of physiologi-
cal EGFR levels at the plasma membrane after EGF-induced 
degradation and that abnormal regulation of this process may 
contribute to uncontrolled proliferation in human carcinomas.
Results
EGF stimulation increases EGFR transport 
efficiency
In a previous study, we have shown that stimulation of HeLa 
cells with high concentrations of EGF can result in up to 80% 
EGFR degradation within 2 h after stimulation (Laketa et al., 
2014), raising the question of how plasma membrane EGFR 
levels can be maintained under these conditions. We hypoth-
esized that EGFR synthesis and transport efficiency along 
the secretory pathway would increase upon EGF stimulation 
in order to restore EGFR levels at the plasma membrane. To 
test this hypothesis, we first monitored endogenous EGFR lo-
calization by immunostaining after continuous stimulation at 
different EGF concentrations. We found that at low EGF con-
centrations (1–10 ng/ml), endogenous EGFR localized mostly 
to the plasma membrane and, to a much lesser extent, to inter-
nal structures (Fig.  1  A). In contrast, at higher EGF concen-
trations (50 ng/ml and 200 ng/ml), the amount of endogenous 
EGFR at the plasma membrane was strongly reduced, and the 
majority of EGFR localized to internal structures most likely 
resembling the ER, as diagnosed by the labeling of reticular 
structures and of the nuclear envelope (Fig. 1 A and Fig. S1). 
Time course analysis showed that stimulation with 200 ng/ml 
EGF for 1 h already results in a significant depletion of EGFR 
at the plasma membrane (Fig. S1). At this time point, EGFR 
localized predominantly to internal structures resembling en-
do-lysosomal structures and, at 6 h or later, to those resembling 
the ER and the Golgi complex (Fig. S1). Interestingly, when 
EGF was washed out and cells chased in EGF-free medium for 
a further 2 h, EGFR plasma membrane levels increased strongly 
(Fig. 1 A). Quantification of the respective fluorescent signals 
showed that the ratio of EGFR at the cell surface to total EGFR 
increased during the chase, consistent with an efficient transport 
of the EGFR from the ER to the plasma membrane (Fig. 1 B). 
This increase was EGF concentration dependent and occurred 
already at 1 ng/ml, although it was most apparent at EGF con-
centrations of 50 ng/ml (32%) and 200 ng/ml (52%; Fig. 1 B). 
We next tested whether EGF stimulation–induced plasma 
membrane EGFR depletion leads to new synthesis of EGFR, 
accounting for the EGFR observed at the ER. We measured the 
mRNA level of EGFR after 24 h of continuous EGF stimula-
tion. This revealed a 2.5-fold increase in the EGFR mRNA level 
compared with nontreated cells (Fig. 2 A). This increase was 
specific for EGF stimulation, as EGFR expression was unaf-
fected by PDGF or insulin-like growth factor (IGF) stimulation 
(Fig. 2 A). We sought for a way to investigate EGF stimulation–
dependent EGFR transport efficiency toward the plasma mem-
brane after synchronized release from the ER. To this end, we 
used a retention using selective hooks (RUSH) expression con-
struct encoding for EGFP-tagged EGFR, which allows for the 
synchronized release of EGFP-EGFR from the ER upon biotin 
treatment (Boncompain et al., 2012). Continuous 200-ng/ml 
EGF stimulation for 24 h increased EGFP-EGFR transport effi-
ciency from the ER to the plasma membrane in cells on average 
by 2.8-fold, whereas PDGF- and IGF-stimulated cells did not 
show any changes (Fig. 2, B and D). Already, 10 ng/ml EGF 
stimulation was sufficient to increase EGFP-EGFR transport ef-
ficiency by 1.4-fold (Fig. S2 A). In contrast, none of the growth 
factor stimulations significantly affected vesicular stomatitis 
virus glycoprotein (VSVG) transport efficiency (Fig. 2, C and 
E). When we analyzed a possible dependence of EGFP-EGFR 
transport efficiency on its expression levels, an inhibition in 
transport efficiency was observed in cells expressing high EG-
FP-EGFR levels compared with those expressing lower levels 
(Fig. S2, B and C). However, the transport efficiency increase 
induced by EGF stimulation in comparison to nontreatment was 
comparable at different expression level intervals (see example 
experiment shown in Fig. S2, C–E).
Next, we asked where the EGFP-EGFR transport change 
between the ER and plasma membrane occurs upon EGF stimu-
lation. To address this, we quantified the arrival of EGFP-EGFR 
at the Golgi complex (Fig.  3). At 15 min after EGFP-EGFR 
release from the ER, a significant amount of EGFP-EGFR had 
already arrived in the Golgi complex, revealed by its colocaliza-
tion with the Golgi marker GM130 (Fig. 3 A). Quantification 
showed that EGFP-EGFR localized to the Golgi complex was 
2.1-fold higher in EGF-stimulated cells when compared with 
nonstimulated cells (Fig. 3 B), suggesting that EGF stimulation 
enhances ER to Golgi transport efficiency. Finally, we com-
pared the EGFP-EGFR transport efficiency of cells exposed to 
continuous EGF stimulation with those exposed to EGF 10-min 
pulse stimulation over different times. Continuous EGF stimu-
lation increased EGFP-EGFR transport efficiency with a max-
imum of 3.7-fold at 18 h, whereas pulse stimulation reached a 
maximum of 2.2-fold at 12 h (Fig. S2 F).
Altogether, these results show that EGF stimulation spe-
cifically increases transport of newly synthesized EGFR to 
maintain its plasma membrane levels.
EGF stimulation up-regulates the inner 
COP II paralogues SEC23B, SEC24B, 
and SEC24D
We next searched for changes in the early secretory pathway that 
could potentially lead to this specific increase in EGFR trans-
port efficiency upon EGF stimulation. Earlier work suggests 
that the transcription of COP II genes is regulated in response to 
increased secretory demands (Shaffer et al., 2004; Abrams and 
Andrew, 2005; Saito et al., 2009; Fox et al., 2010; Iyer et al., 
2013). We therefore tested whether the level of transcription of 
any COP II components was altered by continuous EGF stimu-
lation in parallel with the increase in EGFR synthesis. We found 
that the mRNA levels of the inner COP II paralogues SEC23B, 
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SEC24B, and SEC24D were increased upon 200 ng/ml EGF 
stimulation, with a maximum reached 12  h after stimulation 
(Fig. 4 A and Fig. S3 A). An increase in SEC23B and SEC24D 
mRNA levels was also seen at 10 ng/ml EGF (Fig. S3 B). Stim-
ulation of cells with concentrations of EGF <10 ng/ml had no 
significant effect on the expression of inner COP II paralogues 
(Fig. S3 B). EGF stimulation also increased the mRNA levels of 
the COPI components COPD and ARF1 (Fig. 4 A). Stimulation 
of cells with the growth factors PDGF or IGF had no detectable 
effect on the mRNA levels of SEC23B, SEC24B, SEC24D, or 
Figure 1. EGF stimulation increases endogenous EGFR transport efficiency. (A and B) Endogenous EGFR transport efficiency was determined in HeLa cells 
stimulated for 18 h with 1, 10, 50, or 200 ng/ml EGF. This was followed by a wash out and 2-h chase in starvation medium. (A) Endogenous EGFR protein 
was localized by confocal microscopy either both intracellularly and at the cell surface (total EGFR) or at the cell surface only. Arrowheads point to the nu-
clear envelope in example cells. Images are sum projections of z stacks covering the entire cell volume acquired on a confocal laser-scanning microscope. 
Bar, 10 µm. (B) Quantification of the endogenous EGFR transport efficiency increase percentage in nontreated and stimulated cells calculated as described 
in Materials and methods. Data are means of two independent biological experiments with a minimum of 10,000 analyzed cells per experiment ± SEM.
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COPD, whereas the mRNA levels of ARF1 were increased by 
both EGF and IGF stimulation (Fig.  4  B; unpublished data). 
Further experiments focused on inner COP II paralogues, as they 
showed the largest increase in mRNA levels in response to EGF 
stimulation. Increases in SEC23B and SEC24D mRNA levels 
upon EGF stimulation were validated in A431 cells (Fig. 4 B). 
Moreover, A431 cells, which have high EGFR expression levels 
(Lin et al., 1984), revealed elevated basal expression levels of 
specifically SEC23B and SEC24D in comparison to HeLa cells 
(Fig.  4  C). Altogether, these data show that increased EGFR 
transport efficiency after an extended period of continuous EGF 
stimulation coincides with elevated mRNA levels of the inner 
COP II paralogues SEC23B, SEC24B, and SEC24D in parallel 
to increased EGFR synthesis.
If the increase in transport efficiency of newly synthesized 
EGFR is mediated by SEC23B, SEC24B, and SEC24D, they 
must be up-regulated not only at the RNA level, but also at the 
protein level. To provide evidence for this, we used targeted 
proteomics to quantify the cellular levels of COP II paralogues 
in response to EGF stimulation (Table S3). Our analysis showed 
that 24 h of continuous EGF stimulation increased SEC23B and 
SEC24D protein levels (Fig. 4 D). Furthermore, SEC24A levels 
were also increased (Fig. 4 D), although they were previously 
unaffected at the mRNA level by EGF stimulation. The increase 
in the protein levels of SEC24A could therefore be caused by a 
posttranslational protein regulation mechanism, leading to, e.g., 
reduced protein degradation. Unfortunately, we were unable to 
reliably evaluate SEC24B protein changes by targeted proteom-
ics because of technical limitations.
SEC23B, SEC24B, and SEC24D are 
required for EGFR transport
Selective cargo protein recognition was previously suggested 
to depend on specific inner COP II paralogues and their interac-
tions with cargo-specific ER export motifs (Farhan et al., 2007; 
Wendeler et al., 2007; Bonnon et al., 2010; Merte et al., 2010; 
Sucic et al., 2011). We therefore tested whether the inner COP II 
paralogues up-regulated by EGF stimulation could specifically 
mediate EGFR transport to the plasma membrane. Knockdown 
of the inner COP II paralogues SEC23B, SEC24B, or SEC24D 
Figure 2. EGF stimulation increases EGFP-EGFR transport efficiency to the plasma membrane. HeLa cells were stimulated for 24 h with either 200 ng/ml 
EGF, PDGF, or IGF. This was followed by Q-RT-PCR experiments to study the stimulation effect on EGFR mRNA levels and the RUSH transport assay to study 
the effect on cargo transport efficiency. (A) EGFR log2 mRNA fold change of stimulated cells normalized to nontreated cells and GAP DH mRNA levels. (B 
and C) Quantification of the EGFP-EGFR (B) and EGFP-VSVG (C) transport efficiency of stimulated cells normalized to nontreated cells. a.u., arbitrary units. 
(D and E) Representative cells of EGFP-EGFR (D) and EGFP-VSVG (E) transport from the ER to the plasma membrane in nontreated or EGF-stimulated cells. All 
data are means ± SEM (n = 3; t test: **, P < 0.01; ***, P < 0.001). Images in D and E were acquired on an automated ScanˆR microscope. Bars, 10 µm.
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strongly inhibited EGFP-EGFR transport to levels comparable 
to brefeldin A (BFA) treatment (Fig. 5 A; Lippincott-Schwartz 
et al., 1989; Miller et al., 1992). In contrast, knockdown of 
SEC23A, SEC24A, or SEC24C had no apparent effect on 
EGFP-EGFR transport. Transport of the EGFP-VSVG was not 
significantly affected by any knockdown of inner COP II par-
alogues; only double knockdown of SEC23A and SEC23B re-
sulted in an efficient transport inhibition (Fig. 5 A). In SEC23B 
or SEC23B and SEC23A double knockdown cells, EGFP-EGFR 
remained arrested in the ER, as indicated by the nuclear enve-
lope and reticular network localization of the marker transport 
protein (Fig. 5 B). In contrast, EGFP-EGFR was found at the 
Golgi complex and the plasma membrane in SEC23A knock-
down cells (Fig.  5  B). EGFP-tagged VSVG localized at the 
Golgi complex and the plasma membrane upon release after 
both SEC23A and SEC23B knockdowns (Fig. 5 B). Only dou-
ble knockdown of SEC23A and SEC23B caused EGFP-VSVG 
to be retained mostly in the ER (Fig. 5 B). Collectively, these 
data demonstrate that the inner COP II paralogues SEC23B, 
SEC24B, and SEC24D are required for the transport of EGFR 
from the ER to the plasma membrane.
Identification of putative TRs of SEC23B, 
SEC24B, and SEC24D
As we observed that EGF stimulation specifically increased 
SEC23B, SEC24B, and SEC24D mRNA levels, we set out to 
identify possible TRs mediating the mRNA changes of these 
COP II paralogues. A genome-wide RNAi screen has previously 
identified 554 “hit genes” with a role in secretion (Simpson et 
al., 2012). Using the DNA-binding domain transcription fac-
tor prediction database and the Gene Ontology annotation term 
“DNA binding,” we identified 38 putative TRs among the hit 
genes of this study (Table S4). These putative TRs could po-
tentially regulate secretion through transcriptional control of 
secretory pathway genes. To prioritize the list of TR candidates, 
we performed coexpression analysis and searched for TRs that 
show similar expression patterns with SEC23B, SEC24B, and 
SEC24D under various cellular conditions. For this analysis, we 
used one of the largest publicly available gene expression data-
sets derived from human cell lines subjected to a wide range of 
perturbations (Lamb et al., 2006). We hypothesized that func-
tional related TRs that regulate COP II-mediated EGFR sort-
ing and transport are likely to be coexpressed with SEC23B, 
SEC24B, and SEC24D under different cellular conditions (Stu-
art et al., 2003; van Noort et al., 2003). Finally, the 38 TRs were 
ranked based on their coexpression with SEC23B, SEC24B, 
and SEC24D (see Materials and methods for details; Table S4), 
which revealed ranked candidate TRs that might participate 
in the regulation of the mRNA levels of SEC23B, SEC24B, 
and SEC24D (Fig. 6 A).
RNF11 regulates SEC23B, SEC24B, and 
SEC24D expression and EGFR transport 
efficiency
As the second ranked TR RNF11 (ring finger protein 11; 
Fig.  6 A) has been implicated in EGFR signaling and degra-
dation (Burger et al., 2006; Chen et al., 2008; Kostaras et al., 
2013), we experimentally tested the first two ranked TRs for 
a possible role in the transcriptional regulation of SEC23B, 
SEC24B, and SEC24D. Knockdown of the highest ranked 
TR C1D (C1D nuclear receptor corepressor; Fig. 6 A) had no 
significant effect on SEC23B, SEC24B, and SEC24D mRNA 
levels (Fig. S4 A). On the contrary, RNF11 knockdown specifi-
cally reduced the mRNA levels of SEC23B, SEC24B, SEC24D, 
and also of EGFR (Fig. 6 B). Hence, we analyzed the role of 
RNF11 as a TR of SEC23B, SEC24B, and SEC24D in the con-
text of EGFR signaling in more detail. We found that RNF11-
GFP overexpression specifically increased the mRNA levels of 
SEC23B, SEC24D, and EGFR (Fig. S4 B), although on average 
only 30% of the cells proved to be transfected. We aimed to 
independently confirm these results and overexpressed RNF11 
together with luciferase reporter constructs monitoring the tran-
scriptional activity of the promotor regions of the respective 
inner COP II paralogues. This revealed an enhanced transcrip-
tional activity of SEC24B and SEC24D by 2.3- and 2.4-fold, 
respectively, induced by RNF11 coexpression (Fig. 6 C).
Figure 3. EGF stimulation increases EGFP-EGFR transport efficiency to the Golgi complex. HeLa cells were stimulated for 18 h with 200 ng/ml EGF, and 
the RUSH transport assay was performed to study the effect on EGFP-EGFR transport efficiency from the ER to the Golgi complex. (A) Representative cells of 
EGFP-EGFR ER to Golgi transport before (left) and 15 min after biotin-induced EGFP-EGFR release from the ER (right). EGFP-EGFR fluorescence intensity at 
the Golgi complex was investigated using GM130 as a cis-Golgi marker. Images are sum projections of z stacks covering the entire cell volume acquired 
on a confocal laser-scanning microscope. Bar, 10 µm. (B) Quantification of the EGFP-EGFR transport efficiency to the Golgi complex of stimulated cells 
normalized to nontreated cells. Data are means of at least 30 cells per condition ± SEM. a.u., arbitrary units.
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Consistent with the observed RNF11-mediated expres-
sion changes of the COP II paralogues, RNF11 knockdown 
reduced the number of ER exit sites, which were significantly 
labeled for SEC24B (39% reduction compared with control 
treated cells; Fig. 6, D and E). RNF11 overexpression instead 
had the opposite effect and increased the number of ER exit 
sites significantly labeled for SEC24B (27% increase com-
pared with control cells; Fig. S4 C). In contrast, the total num-
ber of SEC31A-positive ER exit sites remained unchanged 
under RNF11 knockdown or overexpression conditions (Fig. 6, 
D and E; and Fig. S4 C).
Next, we down-regulated RNF11 and investigated the 
effect on EGFP-EGFR transport efficiency using the RUSH 
system. To confirm the specificity of the RNF11 knockdown 
phenotype, we used both HeLa wild-type (WT) cells and 
HeLa cells stably expressing mouse mCherry-tagged RNF11 
(MUS-RNF11-mCherry). siRNA targeting of both human and 
mouse RNF11 (RNF11 HS/MUS) caused a 41% reduction of 
EGFP-EGFR transport efficiency in both HeLa WT and MUS-
RNF11-mCherry cells (Fig. 6 F). siRNA targeting of just human 
RNF11 (RNF11 HS) caused a 38% reduction of EGFP-EGFR 
transport efficiency in HeLa WT cells. This decrease in trans-
port efficiency was efficiently rescued in HeLa MUS-RNF11-
mCherry cells (Fig. 6 F). RNF11 was specifically required for 
EGFP-EGFR transport, as EGFP-VSVG transport in HeLa WT 
cells was not affected by RNF11 knockdown under the condi-
tions used here (Fig. S4 D).
Finally, we determined whether RNF11 mediates the in-
creased expression of SEC23B, SEC24B, SEC24D, and EGFR 
and hence the increase in EGFR transport upon EGF stimula-
tion. We found that RNF11 knockdown led to a significantly 
smaller mRNA increase after 12-h EGF stimulation compared 
with control treated cells (Fig. 6 G). Moreover, using the RUSH 
system, we observed that RNF11 knockdown led to a signifi-
cant reduction of the EGFP-EGFR transport efficiency increase 
after 12-h EGF stimulation (Fig. 6 H).
Figure 4. EGF stimulation up-regulates COP II paralogues in HeLa and A431 cells. HeLa cells and A431 cells were stimulated for 12 or 24  h with 
200 ng/ml EGF, PDGF, or IGF. The effect on COP paralogue expression levels was investigated by Q-RT-PCR and targeted proteomics. Q-RT-PCR results 
were normalized to nontreated cells and GAP DH mRNA levels. Targeted proteomics results were normalized to nontreated cells and prelamin A/C protein 
levels. (A) Log2 mRNA fold changes of COP paralogues and EGFR in HeLa cells treated for 12 h with EGF (n = 4). (B) Log2 mRNA fold changes of COP II 
paralogues in A431 cells treated for 24 h with EGF, PDGF, or IGF (n = 6). (C) Basal log2 mRNA fold change expression of COP II paralogues in nontreated 
A431 cells compared with nontreated HeLa cells (n = 3). Data in A–C are means ± SEM (t test; *, P < 0.05; **, P < 0.01; ***, P < 0.001). (D) Log2 
protein abundances of COP II paralogues in HeLa cells treated for 24 h with EGF (n = 3). Data are medians ± median absolute deviation. 
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Collectively, these data support the hypothesis that the 
predicted candidate TR RNF11 is involved in the up-regulation 
of the inner COP II paralogues SEC23B, SEC24B, and SEC24D 
in response to EGF stimulation and is required for EGFR trans-
port to the plasma membrane.
RNF11 appears in the nucleus upon EGF 
stimulation in a PI3K/Akt-dependent manner
Overexpressed RNF11 localizes on early and late endosomes, 
where it participates in EGFR trafficking to lysosomes for deg-
radation (Santonico et al., 2010; Kostaras et al., 2013, 2014). 
In addition, constitutively active serine/threonine-protein ki-
nase Akt was suggested to induce RNF11 localization changes 
to the nucleus (Connor et al., 2005). As RNF11 had previously 
also been proposed to bind DNA (Li and Seth, 2004; Azmi and 
Seth, 2005), we speculated whether RNF11 could directly par-
ticipate in the transcriptional changes of SEC23B, SEC24B, 
and SEC24D in the nucleus. Immunostaining showed that in 
nontreated cells, endogenous RNF11 localized to the cytoplasm 
and punctate structures, which colocalized with the early endo-
some marker EEA1 (Fig. 7 A). We found a partial relocalization 
of RNF11 to the nucleus, starting at 12 h of continuous EGF 
stimulation (Fig.  7, A and B; and Fig.  8 A). Nuclear RNF11 
appearance was EGF concentration dependent and was already 
observed at 10 ng/ml EGF in 38% of the cells and increased with 
higher EGF concentrations, with a maximum at EGF concentra-
tions of 200 ng/ml (78% of cells with nuclear RNF11; Fig. 8, A 
and B). We confirmed the specificity of the endogenous RNF11 
antibody staining in the nucleus by siRNA-mediated knockdown 
of RNF11, which resulted in a strong reduction of the nuclear 
Figure 5. SEC23B, SEC24B, and SEC24D are required for EGFP-EGFR transport. Specificity of inner COP II paralogues for EGFP-EGFR transport efficiency 
was investigated by performing the RUSH transport assay after 48 h of siRNA-mediated COP II gene knockdown. Results were normalized to nonsilencing 
negative control siRNA. In control experiments, the RUSH transport assay was performed after 30 min of BFA treatment or after 48 h of simultaneous 
knockdown of SEC23A and SEC23B. (A) Quantification of the EGFP-EGFR and EGFP-VSVG transport efficiency. Data are means ± SEM (n = 4; t test: 
*, P < 0.05; **, P < 0.01; ***, P < 0.001). a.u., arbitrary units. (B) Representative cells for EGFP-EGFR and EGFP-VSVG transport from the ER to the 
plasma membrane after SEC23A, SEC23B, or simultaneous knockdown (KD) of SEC23A and SEC23B. Arrows point to the plasma membrane, arrowheads 
to the Golgi complex, and dashed arrows to the nuclear envelope. Images have been exposed such that ER staining (on the nuclear envelope) could also 
be seen. Crosses mark cells without EGFP-EGFR/VSVG expression. Images were acquired on an automated ScanˆR microscope. Bar, 10 µm.
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Figure 6. RNF11 is required for the EGF stimulation–induced up-regulations. Coexpression analysis was performed to predict candidate TRs of SEC23B, 
SEC24B, and SEC24D. To experimentally validate the prediction, Q-RT-PCR, luciferase assay, confocal microscopy, and the RUSH transport assay were 
performed in HeLa cells. (A) Top five–ranked candidate TRs coexpressed with SEC23B, SEC24B, and SEC24D. (B) Log2 mRNA fold changes of COP II par-
alogues and EGFR after siRNA-mediated RNF11 knockdown. Results were normalized to nonsilencing negative control siRNA and to GAP DH mRNA levels 
(n = 8). (C) Luciferase assay was performed with luciferase reporter containing inner COP II or GAP DH gene promotor. The luciferase signal was analyzed 
as the ratio of relative luminescence units of RNF11-GFP–transfected cells to GFP-transfected cells in at least two independent biological experiments. (D 
and E) Representative cells (D) and quantification (E) of the RNF11 knockdown effect on the number of SEC24B- and SEC31A-labeled ER exit sites. Arrows 
in insets point to ER exit sites with SEC24B and SEC31A labeling, and arrowheads point to SEC31A sites with reduced SEC24B labeling. Images are max 
projections of z stacks covering the entire cell volume acquired on a confocal laser-scanning microscope. Bar, 10 µm. Data are means with a minimum of 
100 analyzed cells ± standard deviation. (F) Quantification of the EGFP-EGFR transport efficiency in HeLa WT cells and in HeLa cells stably expressing 
mouse RNF11-mCherry (MUS-RNF11-mCherry) after knockdown of the human and mouse RNF11 gene (RNF11 siRNA HS/MUS) or of the human RNF11 
gene (RNF11 siRNA HS; n = 3). Images for the quantification were acquired on an automated ScanˆR microscope. (G) Log2 mRNA fold changes of COP 
II paralogues and EGFR after RNF11 knockdown, followed by 12-h 200-ng/ml EGF stimulation (n = 6). Results are represented as the percentage of fold 
change reductions normalized to the fold changes induced with nonsilencing negative control siRNA, followed by 12-h 200-ng/ml EGF stimulation (100%). 
(H) Quantification of the EGFR transport efficiency of cells after RNF11 knockdown, followed by 12-h 200-ng/ml EGF stimulation (n = 3). All data, except 
when stated otherwise, are means ± SEM (t test: *, P < 0.05; **, P < 0.01; ***, P < 0.001). a.u., arbitrary units.
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and cytoplasmic punctate antibody labeling (Fig. S5, A and B). 
RNF11 intensity in EEA1-positive early endosomes decreased 
over the time course of EGF stimulation, in parallel with its 
increase in the nucleus, whereas the intensity of EEA1-positive 
early endosomes remained unchanged (Fig. 7 C). This finding is 
consistent with a translocation of the RNF11 protein from early 
endosomes to the nucleus under continuous EGF stimulation.
To start to gain mechanistic insight into how RNF11 might 
translocate to the nucleus upon EGF stimulation, we followed 
quantitatively RNF11 localization in cells stimulated with EGF, 
Figure 7. RNF11 appears in the nucleus upon EGF stimulation. Endogenous RNF11 protein localization was investigated by confocal microscopy in HeLa 
cells treated with 200 ng/ml EGF for various times and compared with nontreated cells. (A) Coimmunostaining of endogenous EEA1 and RNF11 after a 
time course of EGF stimulation. Arrowheads mark colocalized structures. (B) Endogenous RNF11 localization after a time course of EGF stimulation. Ar-
rowheads mark RNF11 structures on early endosomes, and arrows point to the nucleus area. Images in A and B are max projections of z stacks covering 
the entire cell volume acquired on a confocal laser-scanning microscope. Bars, 10 µm. (C) Quantification of RNF11/EEA1 punctate structure intensity 
compared with total RNF11/EEA1 intensity per cell. Data are means ± SEM (n = 3; t test: **, P < 0.01; ***, P < 0.001).
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IGF, and transferrin and tested the dependence of RNF11 relo-
cation on Akt signaling. We found that IGF treatment, which 
is known to result in Akt activation, led to a nuclear relocation 
of RNF11 in a comparable number of cells as EGF stimulation 
(Fig. 8, A and B). Additional treatment of cells with a PI3K/
Akt inhibitor strongly reduced the number of cells with nuclear 
RNF11 from 76% to 21% after EGF stimulation and from 66% 
to 40% after IGF stimulation, in agreement with the hypothesis 
that RNF11 relocation to the nucleus induced by EGF or IGF 
stimulation requires PI3K/Akt signaling. Stimulation of cells 
with transferrin had no apparent effect on RNF11 localization, 
and nuclear RNF11 was observed in <10% of the cells, similar 
to nontreated cells (Fig. 8 B).
Discussion
EGF stimulation of cells results in EGFR internalization, fol-
lowed by its significant degradation via the endo-lysosomal 
pathway. This raises the question of how EGFR levels at the 
cell surface are maintained under situations of continuous 
EGF stimulation. In this study, we show that continuous EGF 
treatment of cells results in a depletion of the EGFR at the cell 
surface in an EGF concentration–dependent manner and accu-
mulation of newly synthesized EGFR in internal membranes 
such as the ER and Golgi complex. Under these conditions, 
EGFR biosynthesis is increased two- to threefold coincident 
with an enhancement of EGFR transport from the ER to the 
Figure 8. RNF11 relocation is PI3K/Akt dependent. Endogenous RNF11 protein localization was investigated by confocal microscopy in HeLa cells 
nontreated or stimulated for 12 h with 1, 10, or 200 ng/ml EGF, 200 ng/ml IGF, or 300 µg/ml transferrin (TF). Stimulations were additionally combined 
with 1 µM PI3K/Akt inhibitor treatment. (A) Staining of the nucleus and immunostaining of endogenous RNF11. Images are max projections of z stacks 
covering the entire cell volume acquired on a confocal laser-scanning microscope. Bar, 10 µm. (B) Quantification of the percentage of cells with nuclear 
RNF11 staining. Data are means with at least 200 analyzed cells per condition ± SEM of different fields of view.
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cell surface. This is accompanied by RNF11-dependent up- 
regulation of the inner COP II paralogues SEC23B, SEC24B, 
and SEC24D, which themselves are specifically required for 
EGFR plasma membrane transport. Altogether, our work iden-
tifies a new mechanism to maintain cell surface EGFR homeo-
stasis after receptor degradation.
Our observation that EGF stimulation induces new syn-
thesis of EGFR in a concentration-dependent manner is in 
agreement with earlier work (Earp et al., 1986; Roepstorff et 
al., 2009). The identified increase in EGFR transport to the 
cell surface, as found for the first time in this study, was also 
EGF concentration dependent and was stronger after contin-
uous EGF stimulation in comparison to a short stimulation 
pulse. Our localization experiments monitoring endogenous 
EGFR provide evidence that this enhanced EGFR transport is 
most likely caused by persistent EGFR internalization from the 
plasma membrane, followed by its degradation and an increased 
requirement to transport newly synthesized EGFR to the plasma 
membrane, situations that we on purpose achieved using high 
EGF concentrations over a long time period of continuous 
stimulation. We were able to measure increased EGFR trans-
port efficiency from the ER to the plasma membrane upon EGF 
stimulation either by monitoring endogenous EGFR during a 
starvation-medium chase after EGF stimulation or alternatively 
by quantifying the transport of an EGFP-EGFR RUSH trans-
port marker that can be retained in the ER and released from it 
by biotin addition, thereby allowing its synchronized transport 
through the secretory pathway. This synchronized transport of 
EGFP-EGFR RUSH revealed that transport after EGF stimu-
lation occurs at the ER/Golgi boundary, as the marker arrived 
more efficiently in the Golgi complex compared with control 
cells after a short period of release from the ER. The increased 
EGFR transport efficiency was observed only at extended peri-
ods of time after EGF stimulation, indicating that the transport 
efficiency increase observed here is caused by long-term cel-
lular adaptations, e.g., by transcriptional changes of transport 
machinery, rather than by posttranslational modifications of 
transport machinery by rapid signaling as previously described 
(Palmer et al., 2005; Farhan et al., 2010; Sharpe et al., 2011). In 
line with this notion, we found that mRNA levels of SEC23B, 
SEC24B, and SEC24D, components of the inner COP II com-
plex that mediates ER exit, increased in parallel to new EGFR 
synthesis upon long-term EGF stimulation. The observed EGF 
stimulation–induced up-regulations of COP II components were 
subtle but appear to be sufficient to help to maintain EGFR levels 
at the plasma membrane under continuous EGF stimulation. In 
line with this view, other fundamental biological processes have 
also been shown to be regulated by subtle transcript alterations 
(Hughes et al., 2000; Mootha et al., 2003; Ori et al., 2015).
Based on our data, at least two different explanations for 
the dependence of EGFR transport on RNF11 function exist. 
First, upon EGF-induced EGFR degradation, an RNF11-in-
dependent mechanism leads to the up-regulation of SEC23B, 
SEC24B, and SEC24D, and hence to adapted EGFR transport. 
The RNF11 requirement in this case might arise from its role on 
early endosomes (Kostaras et al., 2013, 2014), where its levels 
are critical to balance between EGFR degradation and recycling 
(Kostaras et al., 2013). Alternatively, a more intriguing possi-
bility is that RNF11 itself transmits the signal of EGFR degra-
dation from early endosomes into the nucleus, where it directly 
or indirectly participates in the transcriptional regulation of 
SEC23B, SEC24B, and SEC24D. Although we cannot exclude 
the first scenario, the latter is supported by several of our ob-
servations. First, after EGF stimulation, the fraction of RNF11 
protein on early endosomes is reduced, and RNF11 appears in 
the nucleus. Second, the first appearance of RNF11 in the nu-
cleus at 12 h after EGF stimulation is in line with the time point 
of increased SEC23B, SEC24B, and SEC24D mRNA levels 
and enhanced EGFR transport, consistent with the hypothesis 
that nuclear RNF11 is required for the transcriptional changes 
of these COP II paralogues. In further support of this scenario, 
RNF11 has been shown to bind DNA (Li and Seth, 2004; Azmi 
and Seth, 2005), and we show that its overexpression results 
in an increase in the efficiency of luciferase-based SEC24B 
and SEC24D reporters measuring the promotor activity of the 
respective genes. Interestingly, the up-regulation of SEC23B 
by EGF stimulation appears to follow a different mechanism. 
Although we find that RNF11 is sufficient to mediate mRNA 
changes of SEC23B, it was not sufficient to increase the effi-
ciency of the SEC23B-specific luciferase reporter. A possible 
mechanism for SEC23B up-regulation by EGF stimulation 
could be by mRNA stabilization mechanisms involving RNF11. 
For a transcriptional up-regulation of SEC23B, additional fac-
tors to RNF11 would be required.
In our experiments, we have started to explore how 
RNF11 relocates to the nucleus mechanistically, and we found 
that RNF11 nuclear appearance was achieved not only by EGF 
but also by IGF stimulation. In both cases, RNF11 nuclear ap-
pearance was inhibited by a PI3K/Akt inhibitor, consistent with 
earlier findings showing that EGF or IGF is able to trigger PI3K/
Akt signaling efficiently (Vivanco and Sawyers, 2002; Ma et al., 
2015). These results were surprising because IGF stimulation 
had no effect on EGFR transport or COP II component expres-
sion levels, both shown here to require RNF11. One explanation 
for these results could be that IGF-induced nuclear RNF11 is not 
sufficient to mediate the up-regulation of SEC23/SEC24 com-
ponents on its own, and factors additional to RNF11 are neces-
sary to mediate the EGF-stimulated up-regulation of SEC23/24 
and EGFR transport. The existence of such factors might also 
explain the significant but rather moderate effects of RNF11 
knockdown or overexpression on SEC23/24 mRNA levels.
We show that EGF stimulation up-regulated, in an 
RNF11-dependent manner, specifically SEC23B, SEC24B, 
and SEC24D, but not other COP II paralogues, excluding a 
general increase in expression of secretory transport machinery 
upon EGF stimulation. We find that SEC23B, SEC24B, and 
SEC24D are specifically required for the transport of EGFR 
and show with the example of SEC24B that RNF11 knock-
down reduces the number of ER exit sites containing signifi-
cant amounts of SEC24B, whereas the number of ER exit sites 
containing the outer COP II component SEC31 remains unaf-
fected. This suggests that RNF11 perturbation does not affect 
the formation of functional COP II vesicles as such, but rather 
reduces the amounts of specific COP II components required 
for EGFR transport. The identification of paralogue-specific 
EGFR transport strongly supports the proposed role of inner 
COP II paralogues in cargo-specific transport signal recogni-
tion and subsequent cargo-specific ER export (Wendeler et 
al., 2007; Bonnon et al., 2010; Jensen and Schekman, 2011; 
Zanetti et al., 2011). Whereas it is tempting to speculate that 
this is a general mechanism for the transport of different cargo 
proteins, we show that inner COP II paralogues exhibit redun-
dant functions for the transport of VSVG, as well as other 
cargoes such as TNF (unpublished data). This suggests the 
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coexistence of cargo proteins that require specific paralogues 
for their transport and cargo proteins that are transported by 
one or another paralogue.
EGF concentrations as low as 10 ng/ml also induced 
RNF11 translocation to the nucleus, increased mRNA levels 
of SEC23/24 genes, and increased EGFR transport efficiency, 
suggesting that these effects are EGF specific and are not in-
duced by, e.g., cellular stress or unfolded protein response, 
as they may occur under high EGF concentrations (e.g., 
200 ng/ml). EGF concentration in the serum has been mostly 
reported to occur between 0.2 and 2 ng/ml (Joh et al., 1986; 
Nexø et al., 1992; Marquèze-Pouey et al., 2014). At these low 
EGF concentrations, the effects described here could not be 
detected in our experimental setups. However, in this context, 
it is worth noting that growth factor concentrations in tumors 
can become excessively high locally compared with plasma 
concentrations (Stockhammer et al., 2000; Salmaggi et al., 
2003). This has not been shown for EGF. However we believe 
that it is not unreasonable to speculate that EGF concentra-
tions also could be excessively high locally in tumors. In this 
case, the mechanism of continuous EGFR degradation from 
the plasma membrane described here, subsequent increased 
EGFR synthesis, and EGFR transport will be extremely in-
teresting and of high pathophysiological relevance. Along 
this line, RNF11 was found to be overexpressed in breast and 
prostate cancer (Kitching et al., 2003; Subramaniam et al., 
2003). We show that RNF11 overexpression is sufficient to 
increase the expression of EGFR and of those COP II paral-
ogues required for EGFR transport to the plasma membrane. 
Whether abnormal EGFR cell surface levels linked to RNF11 
overexpression could play a critical role in cancer will be an 
interesting question for future research.
Materials and methods
Cell lines and reagents
HeLa Kyoto cells, A431 cells, and HeLa Kyoto cells stably ex-
pressing mouse RNF11-mCherry-LAP (MCB_7996) in a bacterial 
artificial chromosome were cultured in DMEM (Thermo Fisher Sci-
entific) supplemented with 10% FCS (PAA Laboratories GmbH) and 
1% l-glutamine (Sigma-Aldrich) at 37°C in 5% CO2. HeLa Kyoto 
cells stably expressing mouse RNF11-mCherry-LAP were generated 
as previously described (Poser et al., 2008). Experiments were per-
formed 24 h after seeding the cells. Antibodies were used as follows: 
rabbit RNF11 (HPA045781; used at a 1:43 dilution; Atlas Antibod-
ies), mouse GFP (11814460001; clones 7.1 and 13.1, used at a 1:100 
dilution; Roche), mouse SEC31A (612351; clone 32, used at a 1:50 
dilution; BD), mouse EEA1 (610457; clone 14, used at a 1:100 di-
lution; BD), rabbit SEC24B (12042; used at a 1:100 dilution; Cell 
Signaling Technology), mouse anti-VG (used at a 1:100 dilution; gift 
from T.  Kreis, University of Geneva, Geneva, Switzerland), mouse 
EGFR detecting an extracellular EGFR domain (sc-101; clone R-1, 
used at a 1:250 dilution; Santa Cruz Biotechnology, Inc.), and rab-
bit EGFR (sc-03; clone 1005, used at a 1:500 dilution; Santa Cruz 
Biotechnology, Inc.). All goat Alexa Fluor–conjugated secondary 
antibodies were purchased from Thermo Fisher Scientific or Mo-
lecular Probes (A21236 and A11001 were used at a 1:200 dilution 
and A11011 and A11008 at a 1:400 dilution). The following chem-
icals were purchased from Sigma-Aldrich: DAPI, d-biotin, EGF, 
PDGF-BB, IGF-I, apo-transferrin, and BFA. PI3K/Akt inhibitor (Fan 
et al., 2006) was obtained from Selleckchem.
Growth factor experiments
HeLa Kyoto cells were grown in 6-well culture dishes (Thermo 
Fisher Scientific) for 24 h in complete medium at 37°C in 5% CO2. 
Thereafter, the medium was exchanged to medium without FCS for 
24 h. HeLa cells were then treated with 1, 10, 50, 100, or 200 ng/ml 
EGF, 200 ng/ml PDGF-BB or IGF-I, or 300 µg/ml apo-transferrin for 
times as stated (control cells remained nontreated). After this, cells 
were used for RUSH transport assay, endogenous EGFR transport 
assay, quantitative real-time-PCR (Q-RT-PCR), targeted proteomics, or 
immunostaining experiments.
RNAi experiments
For RNAi experiments, HeLa Kyoto cells were grown in 6-well culture 
dishes for 24 h in complete medium at 37°C in 5% CO2. Cells were trans-
fected with the SilencerSelect siRNAs (Thermo Fisher Scientific) listed 
in Table S1 using Lipofectamine 2000 transfection reagent (Invitrogen) 
according to the manufacturer’s instructions. Final siRNA concentra-
tions were 15 nM for all siRNAs. For Q-RT-PCR or immunostaining 
experiments, cells were lysed or fixed after 48-h siRNA transfection. For 
siRNA experiments followed by the RUSH transport assay (see RUSH 
transport assay section), cells were transfected with RUSH constructs 
24 h after siRNA transfection and then incubated for another 24 h. For 
siRNA experiments followed by growth factor stimulation (see the pre-
vious section), after 24 h of siRNA transfection, cells were treated with 
medium without FCS for 24 h and then growth factor stimulated for times 
as stated. If the RUSH assay (see RUSH transport assay section) was ad-
ditionally performed, cells were transfected with RUSH constructs 24 h 
before growth factor treatment was over and incubated for 24 h.
GFP-cDNA overexpression
HeLa Kyoto cells were grown in 6-well culture dishes for 24 h in com-
plete medium at 37°C in 5% CO2. Afterward, cells were transfected with 
a human RNF11 cDNA clone carboxy-terminally linked to turboGFP 
(pCMV6-AC-GFP; OriGene) using FuGENE6 (Roche) according to 
the manufacturer’s instructions. 24 h after transfection, cells were lysed 
and used for Q-RT-PCR experiments or fixed and immunostained.
Q-RT-PCR
For the analysis of mRNA levels, cells were grown in 6-well culture 
dishes for 24 h in complete medium at 37°C in 5% CO2. Cells were 
lysed, and total RNA was extracted using the InviTrap Spin Universal 
RNA Mini kit (Stratec Molecular). cDNA was obtained using the Su-
perScript III First-Strand Synthesis SuperMix (Invitrogen), all accord-
ing to the manufacturer’s instructions. The Q-RT-PCR was performed 
in internal triplicates with the specific and efficient (efficiency between 
90 and 110%) primer pairs (Sigma-Aldrich) listed in Table S2. The 
Q-RT-PCR reaction was performed using the SYBR green detection 
reagent (Applied Biosystems) in StepOne Real-Time PCR System 
machines (Applied Biosystems) using the StepOne software v2.3, all 
according to the manufacturer’s instructions with standard Q-RT-PCR 
cycling conditions. For each biological condition, the fold change 
(2−ΔΔCT) of target mRNA was normalized to that of GAP DH.
Endogenous EGFR transport assay
HeLa Kyoto cells were grown on 15-mm glass coverslips in 6-well 
culture dishes for 24 h in complete medium at 37°C in 5% CO2. The 
medium was exchanged to medium without FCS for another 24 h. Cells 
were stimulated with various concentrations of EGF for 18 h. Thereafter, 
cells were fixed and stained or washed and incubated for a further 2 h in 
starvation medium before fixation and staining. Cell surface EGFR was 
detected using a primary mouse anti-EGFR antibody recognizing an ex-
tracellular EGFR domain and a secondary Alexa Fluor 647 anti–mouse 
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antibody. This was followed by cell permeabilization and total EGFR 
detection using a primary rabbit anti-EGFR antibody and a secondary 
Alexa Fluor 488 anti–rabbit antibody. DAPI staining (0.2-µg/ml final 
concentration) was performed to highlight the nucleus. Images of the nu-
cleus (DAPI), total EGFR (A488), and plasma membrane EGFR (A647) 
were acquired on an automated ScanˆR microscope (Olympus) with 
an Orca R2 camera (Hamamatsu Photonics) and a UPlanAPO 20×/0.7 
NA air objective using the software ScanR 2.1.0.15. 100 positions per 
coverslip were imaged with roughly 100 cells per position, which led 
to at least 10,000 imaged cells per condition. The transport efficiency to 
the plasma membrane was determined as the ratio of cell surface EGFR 
fluorescence (A647 signal intensity) to total EGFR fluorescence (A488 
signal intensity) as previously described (Simpson et al., 2007, 2012). 
The mean transport efficiency was calculated from individual cells for 
each condition, and the EGFR transport efficiency increase was calcu-
lated by the following formula: (Ratio (2h) − Ratio (0h))/Ratio (0h). 
RUSH transport assay
HeLa Kyoto cells were grown on 15-mm glass coverslips in 6-well 
culture dishes for 24 h in complete medium at 37°C in 5% CO2. There-
after, cells were transfected with RUSH cDNA expression constructs 
encoding for EGFP-tagged EGFR or VSVG using Lipofectamine LTX 
(Thermo Fisher Scientific), according to the manufacturer’s instruc-
tions. The VSVG RUSH construct was cloned as previously described 
(Boncompain et al., 2012). The RUSH expression construct for EGFR 
contained the ER hook streptavidin-KDEL. Human EGFR gene ex-
cluding its endogenous signal peptide was purchased as a synthetic 
gene. To generate the RUSH plasmid Str-KDEL_SBP-EGFP-EGFR, 
human EGFR fragment was inserted downstream of the IL2 signal pep-
tide-SBP-EGFP cassette using the FseI and PacI restriction sites. Endo-
cytosis of SBP-EGFP-EGFR after exposure to 50 ng/ml human EGF of 
HeLa cells expressing RUSH EGFR in the presence of biotin was ob-
served, confirming that the RUSH EGFR construct is functional. RUSH 
constructs were expressed for 24 h. Thereafter, release of the RUSH 
constructs was induced by the addition of biotin for 15 min (for ER 
to Golgi transport) or 45 min (for ER to plasma membrane transport) 
at a final concentration of 40 µM in the culture medium as previously 
described (Boncompain et al., 2012). The release was additionally 
performed in the presence of 100 µg/ml cycloheximide to stop new 
protein synthesis. In parallel, a control sample to monitor leakiness of 
the RUSH construct–encoded cargo protein before the release was left 
for each condition without biotin (no release). After the release, cells 
were fixed and immunostained as previously described (Boncompain 
and Perez, 2014). In brief, primary antibody staining was performed 
using mouse anti-GFP antibody for EGFP-EGFR or mouse anti-VG an-
tibody for EGFP-VSVG and secondary antibody staining using Alexa 
Fluor 647 anti–mouse antibody and DAPI staining to highlight the 
nucleus. When the RUSH assay was performed after siRNA-mediated 
gene knockdown, cell lysates were additionally taken from the 6-well 
culture dishes, and Q-RT-PCR experiments were performed to con-
firm the siRNA-mediated mRNA reduction of the investigated genes. 
Only samples with at least 80% mRNA reduction were used for im-
munostaining. Images of the nucleus (DAPI), total EGFP-EGFR/EG-
FP-VSVG (A488), and plasma membrane EGFP-EGFR/EGFP-VSVG 
(A647) were acquired on an automated ScanˆR microscope with an 
Orca R2 camera and UPlanAPO 20×/0.7 NA air objective using the 
software ScanR 2.1.0.15. 100 positions per coverslip were imaged with 
roughly 100 cells per position, which led to at least 10,000 imaged cells 
per condition. Images were analyzed automatically using CellProfiler 
version 2.0.11047. In brief, based on predefined size and shape param-
eters, stained nuclei were detected. Subsequently, the borders of single 
cells were estimated based on digital dilation of the nuclei masks. A488 
and A647 fluorescence signal intensities were measured within the sin-
gle cell areas. The transport efficiency to the plasma membrane was 
determined as the ratio of cell surface EGFP-EGFR/EGFP-VSVG flu-
orescence (A647 signal intensity) to total EGFP-EGFR/EGFP-VSVG 
fluorescence (A488 signal intensity) as previously described (Simpson 
et al., 2007, 2012). For each condition, the mean transport ratio was 
calculated from individual cells and corrected to the mean transport 
ratio of the cells at no release. Only cells expressing EGFP-EGFR/ 
EGFP-VSVG (transfected) were analyzed, which was defined by using 
the total values (A488 signal intensity) of cells without EGFP-EGFR/
EGFP-VSVG expression (untransfected) as a threshold.
Targeted proteomics
Targeted proteomics assays for COP II components were developed as 
previously described (Ori et al., 2014). In brief, proteotypic peptides 
for the COP II components SEC23A, SEC23B, SEC24A, SEC24B, 
SEC24C, SEC24D, and SEC31A were selected from an in-house build 
spectral library generated from HeLa Kyoto total cell lysate. Isotopi-
cally labeled versions of the selected peptides were synthetized (JPT 
Technologies) and used for assay development and as spike-in inter-
nal standards. Two proteotypic peptides were used for relative protein 
quantification across samples, with the exception of SEC31A, for 
which four proteotypic peptides were used. Two additional peptides 
derived from prelamin A/C were included and used to normalize pep-
tide ratios across samples (i.e., to account for variations in the amount 
of internal standard peptides that were spiked in). Control (nontreated) 
and 24-h EGF-stimulated cells were lysed and digested into peptides 
as described previously (Ori et al., 2014). After protein digestion, de-
salted peptides were spiked in with a pool of synthetic peptides for 
COP II components and iRT-kit (Biognosys AG) for retention time cal-
ibration (Escher et al., 2012). Assays for both the endogenous (light) 
and reference (heavy) peptides were recorded in schedule mode using 
a triple quadrupole mass spectrometer (TSQ Vantage) connected to a 
nanoAcquity ultra performance liquid chromatography (UPLC) system 
(Waters). Digested peptides were separated on a BEH300 C18 (75 µm 
× 250 mm, 1.7 µm) nanoAcquity UPLC column with a 75-min linear 
gradient between 3 and 35% (vol/vol) acetonitrile in 0.1% (vol/vol) 
formic acid at a flow rate of 300 nl/min. Data were recorded using 
scheduled acquisition with a fixed cycle time of 2.5 s, and the number 
of coeluting transitions was limited to 100 per cycle. Data acquisition 
was performed using 4-min-long time windows centered around the ap-
proximate retention time of targets relative to the iRT-kit. Peptide ratios 
were estimated using the summed intensity of all transitions and nor-
malized to the mean ratio of the prelamin A/C peptides across samples. 
Protein fold changes were estimated using linear mixed-effect models 
(as implemented in R package ‘nlme;’ version 3.1–103) as described 
previously by Ori et al. (2013). Assay refinement, recalibrations, and 
data analysis were performed using SpectroDive (Biognosys AG).
Coexpression analysis
For coexpression analysis, the Connectivity Map resource was used, 
which contains 6,100 gene expression profiles from four human cancer 
cell lines treated with more than a thousand drug-like molecules (Lamb 
et al., 2006). To minimize batch effect, normalization and filtering steps 
were performed as described previously (Iskar et al., 2010). 990 drug-
induced gene expression profiles from the human cancer cell lines HL60, 
MCF7, and PC3 were analyzed (see supplemental data in Iskar et al., 
2013). In each cell line, probe sets were filtered if not called “present” 
in >50% of the experiments. For genes represented by multiple probe 
sets, the probe set with the highest variance (ranked highest in mean 
across three cell lines) was selected as the representative of the gene. 
Large-scale coexpression analysis was performed on all 554 secretion 
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screen “hit genes” (Simpson et al., 2012) that are known or predicted to 
be transcription regulators, as determined by their presence in the DNA-
binding domain: Transcription factor prediction database (Wilson et al., 
2007) or their annotation with the GO term “DNA-binding activity” 
(GO :0003677). The list of TRs was limited to available probe sets 
that were measured in the Connectivity Map resource by the HT_
HG-U133A microarray platform. In total, from the 554 hit genes, 38 
TRs detected as “present” in at least two out of three cell lines were 
retained for further analysis. Drug-induced gene expression profiles 
from three cell lines were used to calculate all the pairwise Pearson’s 
correlations between TRs and the SEC23B, SEC24B, and SEC24D 
COP II components. For each TR, an average coexpression similarity 
was calculated in each cell line by averaging their Pearson correlation. 
Next, we used the nonparametric rank product (RankProd) method to 
assess the significance of coexpression similarity (Hong et al., 2006). 
RankProd combines the ranked lists of coexpression values from 
multiple cell lines to identify TRs significantly coexpressed with the 
COP II components SEC23B, SEC24B, and SEC24D. Finally, all the 
TRs were ranked based on their corrected p-value (estimated percentage 
of false prediction) in the order of coexpression from high to low.
Confocal microscopy and segmentation analysis
Confocal microscopy experiments were performed with fixed and im-
munostained cell samples on a microscope (LSM780; ZEI SS) with a 
Plan Apochromat 63×/1.4 NA oil differential interference contrast ob-
jective and the ZEN (black edition) 2012 SP1 8.1 software (ZEI SS). 
DAPI was detected by using a 405-nm laser with a 407–489-nm emis-
sion filter; a 488/561-nm laser with a 497–558-nm emission filter was 
used for Alexa Fluor 488–labeled proteins; a 488/561-nm laser with 
a 559–655-nm emission filter was used for Alexa Fluor 568–labeled 
proteins; and a 633-nm laser with a 640–715-nm emission filter was 
used for Alexa Fluor 647–labeled proteins. Z stacks of images cover-
ing the entire cell thickness were acquired. Using ImageJ version 1.46r 
(National Institutes of Health), the stacks were projected (maximum or 
sum intensity), the background was subtracted, and the images were 
smoothed. To determine the number of SEC24B/SEC31A structures 
per cell area, cells were manually segmented, and SEC24B/SEC31A 
structures were determined by thresholding. Only the peripheral struc-
tures were considered, where the space between the punctae allowed 
the segmentation of individual structures. The total number of detected 
structures per cell was then divided by the total cell area. For RNF11/
EEA1 intensity measurements, cells were manually segmented, and 
RNF11/EEA1 structures were determined by thresholding. The fluo-
rescence intensity of detected RNF11/EEA1 punctate structures per 
cell was divided by the total RNF11/EEA1 intensity per segmented cell.
Luciferase assay
HeLa Kyoto cells were grown in 96-well plates for 24  h in com-
plete medium at 37°C in 5% CO2. Luciferase assays were performed 
with the following promoter luminescent reporter gene constructs: 
SEC23A, SEC23B, SEC24B, SEC24C, SEC24D, and GAP DH (Ac-
tive Motif). All promotor constructs were obtained from the Active 
Motif LightSwitch Promoter Reporter GoClone Collection (Trinklein 
et al., 2003). Cells were cotransfected with 50 ng GoClone plasmid 
DNA per well and with 10 ng of either turboGFP-tagged RNF11 or 
GFP empty vector according to the manufacturer’s instructions (Active 
Motif). Plasmid DNA expression time was 24 h for all experiments. 
Luciferase reporter signal was measured with the LightSwitch Lucifer-
ase Assay System (Active Motif) on a SpectraMax L luminometer ac-
cording to the manufacturer’s instructions. Relative luminescence units 
of GFP-expressing cells were normalized to RNF11-GFP–expressing 
cells. To achieve this, in parallel to the 96-well plate for the luciferase 
assay, a 96-well glass-bottom plate was assessed on a standard wide-
field fluorescence microscope for the transfection efficiency of cells 
with GFP or RNF11-GFP in each well. Relative luminescence units 
measured in the wells of GFP-expressing cells were then corrected for 
the higher expression efficiency (on average 1.5-fold higher) compared 
with RNF11-GFP–expressing cells.
Statistical analysis
All data were analyzed for significance using a Welch’s t test. Effects 
were compared with nontreated samples or samples treated with non-
silencing negative control siRNA and were considered as significant if 
the p-values were *, P < 0.05; **, P < 0.01; or ***, P < 0.001.
Online supplemental material
Fig. S1 illustrates endogenous EGFR protein localizations induced 
by EGF stimulation for various times. Fig. S2 illustrates EGF 
stimulation–induced EGFP-EGFR transport efficiency changes. Fig. 
S3 demonstrates the mRNA level changes of inner COP II components 
and EGFR caused by EGF stimulation. Fig. S4 shows the effect of 
C1D knockdown and RNF11 overexpression on inner COP II gene 
expression and the effect of RNF11 knockdown on EGFP-VSVG 
transport. Fig. S5 illustrates the validation of the RNF11 siRNA 
knockdown efficiency. Table S1 is a list of the used siRNAs. Table 
S2 is a list of the used primer pairs. Table S3 contains the designed 
assay parameters for the targeted proteomics analysis. Table S4 is the 
ranked list of TRs coexpressed with SEC23B, SEC24B, and SEC24D. 
Additional data are available in the JCB DataViewer at https ://doi .org 
/10 .1083 /JCB .201601090 .dv.
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